



Amicus Therapeutics Announces Presentations at the 26th International Annual Congress of the World Muscle Society

September 20, 2021

PHILADELPHIA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- [Amicus Therapeutics](#) (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the [26th International Annual Congress of the World Muscle Society \(WMS\)](#) being held virtually, September 20-24, 2021.

ePoster Presentations:

- *Cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease: PROPEL study subgroup analyses*
 - Presenter: Mark Roberts, MD, Consultant Neurologist, Salford Royal NHS Foundation Trust, Greater Manchester Neurosciences Centre, United Kingdom (ePoster #196)
- *Living with late-onset Pompe disease in the UK: interim results characterising the patient journey and burden on physical, emotional and social quality of life*
 - Presenter: Allan Muir, Chair of the Board of Trustees, Pompe Support Network, United Kingdom (ePoster #201)

Cipaglucosidase alfa/miglustat is an investigational therapy that is not yet approved by any regulatory agency.

The posters will be made available on the Amicus [website](#) following their respective presentations at the congress.

For more information on the 26th International Annual Congress of the World Muscle Society, please visit www.wms2021.com.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company's website at www.amicusrx.com, and follow us on [Twitter](#) and [LinkedIn](#).

CONTACT:

Investors:

Andrew Faughnan
Executive Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:

Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD-G